Dementia is an acquired syndrome in which intellectual ability decreases to the point that it interferes with daily function. Dementia is a term used to describe a group of symptoms common to certain diseases or conditions.More particularly, it pertains to a drug delivery device for the controlled delivery of venlafaxine and the rapid delivery of a drug used to treat Alzheimer's disease or Parkinson's disease. This invention pertains to a drug delivery device containing an anti-depressant and an anti-Alzheimer's agent.lactose, mannitol Derivatives thereof, e.g. A61K9/2018- Sugars, or sugar alcohols, e.g.A61K9/2004- Excipients Inactive ingredients.amphetamine, epinephrine, salbutamol, ephedrine or methadone A61K31/135- Amines having aromatic rings, e.g.A61K31/00- Medicinal preparations containing organic active ingredients. A61K9/0004- Osmotic delivery systems Sustained release driven by osmosis, thermal energy or gas.A61K9/0002- Galenical forms characterised by the drug release technique Application systems commanded by energy.A61K9/00- Medicinal preparations characterised by special physical form.A61K- PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES.A61- MEDICAL OR VETERINARY SCIENCE HYGIENE.Status Abandoned legal-status Critical Current Links Assignors: BIGATTI, GUIDO, MEYER, GLENN A, RICCI, MARCELO A Assigned to OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT reassignment OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from PCT/CR2003/000004 external-priority patent/WO2004056335A2/en Priority claimed from US11/010,829 external-priority patent/US8293799B2/en Application filed by Osmotica Corp filed Critical Osmotica Corp Priority to US11/532,186 priority Critical patent/US20070077301A1/en Publication of US20070077301A1 publication Critical patent/US20070077301A1/en Assigned to OSMOTICA CORP. Original Assignee Osmotica Corp Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Abandoned Application number US11/532,186 Inventor Glenn Meyer Marcelo Ricci Guido Bigatti Current Assignee (The listed assignees may be inaccurate. Google Patents US20070077301A1 - Venlafaxine osmotic device formulation US20070077301A1 - Venlafaxine osmotic device formulation
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |